Market Overview:
The global anti-malarial drug market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of malaria, rising demand for effective and affordable anti-malarial drugs, and growing investments by key players in this market. Based on type, the global anti-malarial drug market can be segmented into plasmodium falciparum, plasmodium vivax, plasmodium malariae, and plasmodium ovale. Of these segments, the plasmodium falciparum segment is expected to account for the largest share of the global anti-malarial drug market in 2018. This segment is also projected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this segment can be attributed to factors such as rising incidence of malaria caused by Plasmodium falciparum and increasing demand for effective and affordable antimalarial drugs against Plasmodium falciparum infections. Based on application, the global anti-malarial drug market can be divided into hospital pharmacy, retail pharmacy, ecommerce channel (direct), and other channels (including direct sales).
Product Definition:
An anti-malarial drug is a type of medication that is used to prevent or treat malaria. Malaria is a disease that is caused by parasites that are spread through the bite of an infected mosquito. Anti-malarial drugs can help to prevent the development of malaria, and they can also be used to treat infections that have already been diagnosed.
Plasmodium Falciparum:
Plasmodium falciparum is the most dangerous species of malaria, which causes over half a million deaths every year. P. falciparum is an intra-erythrozoite parasite and it's DNA sequence has been used as a probe to study the pathogeny of other malarial parasites.
Plasmodium Vivax:
Plasmodium vivax is a species of the malaria parasite. P.vivax is the most prevalent species of Plasmodium found in Africa and Southeast Asia, with over 99% of all malarial parasites being P.vivax. The other two species are P. falciparum (the primary cause of severe malaria) and P. ovale (a minor player).
Application Insights:
The others segment held the largest share of the global anti-malarial drug market in 2017. This is attributed to growing awareness about other drugs with similar structures and mechanisms of action, which are effective against malaria parasites. For instance, mefloquine is a commonly used antimalarials for treatment that has been found to be effective against P. falciparum as well as P. vivax infections owing to its high affinity for erythrocytes and liver stages of parasite life cycle respectively. However, due to its limited usage compared to other drugs in the same category such as artemisinin derivatives and sulfadoxine/pyrimethamine combination therapy, this application segment holds a smaller share in Asia Pacific region than it does globally (see table below).
Regional Analysis:
Asia Pacific dominated the global market in 2017 and is expected to continue its dominance over the forecast period. The region accounts for a large share of the overall population affected by malaria, which is around 90% of 785 million people in 2016. Moreover, this region has one of the highest number of under-treated patients suffering from malaria as compared to other regions with high treatment coverage. According to WHO data, only 39% (excluding China) have access to antimalarial drugs in 2015 despite it being one of WHO's 10 strategic priorities.
The increasing prevalence rate and geographical expansion are among key factors driving growth across Asia Pacific countries such as India.
Growth Factors:
- Increasing incidence of malaria: The increasing incidence of malaria is one of the key growth drivers for the anti-malarial drug market. According to World Health Organization (WHO), there were around 214 million cases of malaria and 438,000 deaths due to it in 2015. This number is expected to increase in the coming years, thereby driving demand for anti-malarial drugs.
- Growing awareness about prevention and treatment: There is a growing awareness among people about prevention and treatment of malaria. This is resulting in an increase in demand for anti-malarial drugs worldwide.
- Rising prevalence of drug resistance: The prevalence of drug resistance is another major growth driver for the global anti-malarial drug market . Drug resistance develops when a parasite becomes resistant to one or more drugs used to treat it .This has been a major challenge faced by researchers and manufacturers involved in this market over the past few years . To overcome this challenge, new molecules are being developed which are likely to fuel market growth during the forecast period .
Scope Of The Report
Report Attributes
Report Details
Report Title
Anti-Malarial Drug Market Research Report
By Type
Plasmodium Falciparum, Plasmodium Vivax, Plasmodium Malariae, Plasmodium Ovale
By Application
Hospital Pharmacy, Retail Pharmacy, E-Commerce, Others
By Companies
GlaxoSmithKline, Ranbaxy, Zydus Cadila, Alvizia, Bayer, Ipca, Merck, F. Hoffmann-La Roche, Novartis, Pfizer, GlaxoSmithKline
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
170
Number of Tables & Figures
119
Customization Available
Yes, the report can be customized as per your need.
Global Anti-Malarial Drug Market Report Segments:
The global Anti-Malarial Drug market is segmented on the basis of:
Types
Plasmodium Falciparum, Plasmodium Vivax, Plasmodium Malariae, Plasmodium Ovale
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacy, Retail Pharmacy, E-Commerce, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GlaxoSmithKline
- Ranbaxy
- Zydus Cadila
- Alvizia
- Bayer
- Ipca
- Merck
- F. Hoffmann-La Roche
- Novartis
- Pfizer
- GlaxoSmithKline
Highlights of The Anti-Malarial Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Plasmodium Falciparum
- Plasmodium Vivax
- Plasmodium Malariae
- Plasmodium Ovale
- By Application:
- Hospital Pharmacy
- Retail Pharmacy
- E-Commerce
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Anti-Malarial Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
An anti-malarial drug is a medication used to treat malaria.
Some of the key players operating in the anti-malarial drug market are GlaxoSmithKline, Ranbaxy, Zydus Cadila, Alvizia, Bayer, Ipca, Merck, F. Hoffmann-La Roche, Novartis, Pfizer, GlaxoSmithKline.
The anti-malarial drug market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Anti-Malarial Drug Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Anti-Malarial Drug Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Anti-Malarial Drug Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Anti-Malarial Drug Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Anti-Malarial Drug Market Size & Forecast, 2020-2028 4.5.1 Anti-Malarial Drug Market Size and Y-o-Y Growth 4.5.2 Anti-Malarial Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Plasmodium Falciparum
5.2.2 Plasmodium Vivax
5.2.3 Plasmodium Malariae
5.2.4 Plasmodium Ovale
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital Pharmacy
6.2.2 Retail Pharmacy
6.2.3 E-Commerce
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Anti-Malarial Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Anti-Malarial Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Plasmodium Falciparum
9.6.2 Plasmodium Vivax
9.6.3 Plasmodium Malariae
9.6.4 Plasmodium Ovale
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital Pharmacy
9.10.2 Retail Pharmacy
9.10.3 E-Commerce
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Plasmodium Falciparum
10.6.2 Plasmodium Vivax
10.6.3 Plasmodium Malariae
10.6.4 Plasmodium Ovale
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital Pharmacy
10.10.2 Retail Pharmacy
10.10.3 E-Commerce
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Plasmodium Falciparum
11.6.2 Plasmodium Vivax
11.6.3 Plasmodium Malariae
11.6.4 Plasmodium Ovale
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital Pharmacy
11.10.2 Retail Pharmacy
11.10.3 E-Commerce
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Plasmodium Falciparum
12.6.2 Plasmodium Vivax
12.6.3 Plasmodium Malariae
12.6.4 Plasmodium Ovale
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital Pharmacy
12.10.2 Retail Pharmacy
12.10.3 E-Commerce
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Plasmodium Falciparum
13.6.2 Plasmodium Vivax
13.6.3 Plasmodium Malariae
13.6.4 Plasmodium Ovale
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital Pharmacy
13.10.2 Retail Pharmacy
13.10.3 E-Commerce
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Anti-Malarial Drug Market: Competitive Dashboard
14.2 Global Anti-Malarial Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 GlaxoSmithKline
14.3.2 Ranbaxy
14.3.3 Zydus Cadila
14.3.4 Alvizia
14.3.5 Bayer
14.3.6 Ipca
14.3.7 Merck
14.3.8 F. Hoffmann-La Roche
14.3.9 Novartis
14.3.10 Pfizer
14.3.11 GlaxoSmithKline